Vaccinex, Inc. (VCNX)
| Market Cap | 32.03M |
| Revenue (ttm) | 900,000 |
| Net Income (ttm) | -24.19M |
| Shares Out | 30.80M |
| EPS (ttm) | -0.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 80,090 |
| Open | 1.07 |
| Previous Close | 1.09 |
| Day's Range | 1.03 - 1.08 |
| 52-Week Range | 1.02 - 9.56 |
| Beta | 1.54 |
| Analysts | Buy |
| Price Target | 7.00 (+573.1%) |
| Earnings Date | n/a |
About VCNX
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that is in Phase 1 and 2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alz...
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for Vaccinex stock is "Buy." The 12-month stock price forecast is 7.00, which is an increase of 573.08% from the latest price.
News
Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurre...
Phase 1b segment evaluated safety and tolerability of the combination
Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
In-person and virtual Presentation: November 10-14th, 2021 In-person and virtual Presentation: November 10-14th, 2021
Vaccinex, Inc. to Present at the Clinical Trials on Alzheimer's Disease (CTAD) Meeting
Live Presentation: Thursday, Nov. 11, 2021 Live Presentation: Thursday, Nov. 11, 2021
Vaccinex Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Enrollment underway in combination Phase 1b/2 study of pepinemab with KEYTRUDA® in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Vaccinex, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference
Virtual Dates: November 18 th – 19 th , 2021
Vaccinex to Present at the Virtual Huntington's Study Group Meeting on November 4-6, 2021
Presentation to highlight expanded post-hoc subgroup analysis of the SIGNAL Phase 2 Huntington's Disease (HD) trial suggesting a cognitive benefit in patients with mildly advanced disease Presentation t...
Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit
ROCHESTER, N.Y., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease and c...
Vaccinex Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Patients are currently being screened and enrolled in two studies of pepinemab as monotherapy in Alzheimer's disease and in combination with KEYTRUDA® in Metastatic Head and Neck Squamous Cell Carcinoma...
Vaccinex to Chair Panel Q&A Session and Present Poster at the XV European Meeting on Glial Cells in Health and Disease
ROCHESTER, N.Y., June 30, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease and ca...
Vaccinex Initiates Pepinemab Trials for Alzheimer's, Head & Neck Cancer
Vaccinex Inc (NASDAQ: VCNX) has activated first clinical sites to screen and enroll patients in its Phase 1/2 study evaluating pepinemab as a single agent in Alzheimer's disease (AD) and in its phase 2 ...
Vaccinex Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheim...
Company plans to activate at least 13 clinical sites for Alzheimer's study and 18 clinical sites for head and neck cancer across the United States Company plans to activate at least 13 clinical sites fo...
Vaccinex Reports First Quarter 2021 Financial Results and Provides Corporate Update
Initiated Phase 2 study of pepinemab in combination with KEYTRUDA® in advanced, recurrent or metastatic head and neck cancer
Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer...
CLASSICAL-Lung study evaluated pepinemab in combination with the checkpoint inhibitor BAVENCIO® for the treatment of non-small cell lung cancer CLASSICAL-Lung study evaluated pepinemab in combination wi...
Vaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update
Reported top-line results from Phase 2 SIGNAL study that indicates potential cognitive benefit of pepinemab in neurodegenerative disease. New Alzheimer's study expected to begin enrollment in Q2
Why Novavax, Vaccinex, Evolus Are Trading Higher Today
Novavax (NASDAQ: NVAX) shares are trading higher Friday after the company announced a Memorandum of Understanding with Gavi to provide 1.1 billion cumulative doses of NVX-CoV2373. Novavax is a biotechno...
Vaccinex stock soars 223% on partnership deals using its antibody discovery platform (VCNX)
Vaccinex stock rocketed up more than 200% Friday, propelled by two collaboration deals centered on using the biotech company's antibody discovery platform. Vaccinex, which focuses on cancer and neurode...
Vaccinex's stock soars toward record gain on record volume after deals with 'prominent' drug makers
Shares of Vaccinex Inc. soared toward a record rally on record volume Friday, after the biotechnology company announced the signing of multiple-project deals with two "prominent" pharmaceutical companie...
VCNX Stock: 11 Things to Know About Vaccinex and the Deals That Have Shares Soaring
Vaccinex (VCNX) stock is rocketing higher on Friday after following an announcement about multi-project deals with two comapnies. The post VCNX Stock: 11 Things to Know About Vaccinex and the Deals That...
Why Vaccinex Shares Are Rallying
Shares of micro-cap biopharma Vaccinex Inc (NASDAQ: VCNX) were trading higher Friday on above-average volume. Rochester, New York-based Vaccinex, which focuses on therapies for cancer and neurodegenerat...
Vaccinex Rallies After Announcing Multi-Project Pact Using Its Antibody Discovery Platform
Vaccinex Inc (NASDAQ: VCNX) jumps premarket in reaction to multi-project deals signed with two undisclosed prominent pharmaceutical companies, utilizing Vaccinex's ActivMAb, antibody discovery, and nove...
Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its...
Partnerships will use Vaccinex's ActivMAb® platform for viral display of complex antigens to enable antibody discovery Partnerships will use Vaccinex's ActivMAb® platform for viral display of complex an...
Vaccinex to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event
ROCHESTER, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative dis...
Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Addition al data from SIGNAL Huntington's disease (HD) trial support continued development in H D and in Alzheimer's disease (AD)
CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference
SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington's disease